CGON (CG Oncology) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CGON CG Oncology Inc CGON
30 GF Score
Price $76.56
GF Value $139.19
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is CG Oncology FFO?

FFO (Funds from operations) only applies to REITs.

CGON
30GF Score
CG Oncology Inc CGON
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CG Oncology (CGON) Overvalued in 2026?

Based on GuruFocus' analysis, CG Oncology stock appears to be undervalued. The current stock price of $76.56 is trading 45% below its estimated GF Value™ of $139.19. GuruFocus considers CG Oncology to be Possible Value Trap.

Key valuation signals for CGON:

  • FFO:
  • GF Value™: $139.19 vs. price of $76.56 (45% below fair value)
  • GF Score™: 30/100 with 6 warning signs

No single metric tells the full story. See the CGON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CG Oncology Business Description

Address 400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
30GF Score

Get the complete analysis for CGON

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$76.56
Price
$139.19
GF Value